Zimmer not only ortho victim of strong dollar
This article was originally published in Clinica
"We believe that both Stryker and Biomet will be affected by the recent strengthening in the dollar." So said Morgan Stanley analysts following an announcement by Zimmer that the improvement of the US dollar against other major currencies would lead to a $49m shortfall in its predicted sales for 2005.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.